Spyre Therapeutics price to sales ratio SYRE

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 90.6×; Feb 2024
8-year median: 14.5×
8-year range: 1.0× to 108×
Peer median: 5.8×

Spyre Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Feb 2024, at 90.6×.

On the days it had one over the last 8 years, its median was 14.5×, from 1.0× in Jul 2022 to 108× in Aug 2019.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	90.6×	82.2×	106×
2023	82.7×	4.2×	82.7×
2022	4.8×	1.0×	14.5×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	108×	51.6×	108×

Against its peers

Companies in Drug Manufacturers - General nearest Spyre Therapeutics' size, closest first, today.

Company	Price to sales ratio
SYRESpyre Therapeutics	n/m
TGTXTG Therapeutics	10.4×
ALKSAlkermes plc.	4.4×
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
AMRXAmneal Pharmaceuticals	2.1×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
BMRNBiomarin Pharmaceutical	3.2×
JAZZJazz Pharmaceuticals	3.0×
INDVIndivior Pharmaceuticals	3.1×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Spyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.